Skip to main content

Table 3 Grade 3–4 treatment-related acute adverse events

From: Using neoadjuvant chemotherapy and replanning intensity-modulated radiotherapy for nasopharyngeal carcinoma with intracranial invasion to protect critical normal tissue

 

During neoadjuvant chemotherapy

During concurrent chemoradiation

Event

Grade 3

Grade 4

Grade 3

Grade 4

Hematological

    

 Leukopenia

15(46.8%)

3(9.3%)

7(21.8%)

1(3.1%)

 Neutropenia

6(18.7%)

18(56.2%)

2(6.2%)

4(12.5%)

 Neutropenia fever

3(9.3%)

0(0.0%)

0(0.0%)

0(0.0%)

 Thrombocytopenia

0(0.0%)

0(0.0%)

3(9.3%)

1(3.1%)

 Anemia

0(0.0%)

0(0.0%)

2(6.2%)

0(0.0%)

Non-hematological

    

 Fatigue

4(12.5%)

0(0.0%)

4(12.5%)

0(0.0%)

 Nausea/vomiting

4(12.5%)

0(0.0%)

4(12.5%)

0(0.0%)

 Ototoxicity

0(0.0%)

0(0.0%)

0(0.0%)

0(0.0%)

 Diarrhea

0(0.0%)

0(0.0%)

0(0.0%)

0(0.0%)

 Liver dysfunction

0(0.0%)

0(0.0%)

0(0.0%)

0(0.0%)

 Kidney dysfunction

0(0.0%)

0(0.0%)

0(0.0%)

0(0.0%)

 Stomatitis

1(3.1%)

0(0.0%)

8(25%)

0(0.0%)

 Dermatitis

-

-

1(3.1%)

0(0.0%)

 Xerostomia

-

-

9(28.1%)

0(0.0%)